Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Inventory (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Inventory for 15 consecutive years, with $9.1 million as the latest value for Q4 2025.

  • Quarterly Inventory fell 35.34% to $9.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.1 million through Dec 2025, down 35.34% year-over-year, with the annual reading at $9.1 million for FY2025, 35.34% down from the prior year.
  • Inventory hit $9.1 million in Q4 2025 for Ligand Pharmaceuticals, down from $11.9 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $39.9 million in Q2 2021 to a low of $9.1 million in Q4 2025.
  • Historically, Inventory has averaged $21.8 million across 5 years, with a median of $21.8 million in 2022.
  • Biggest five-year swings in Inventory: skyrocketed 979.04% in 2021 and later tumbled 51.35% in 2022.
  • Year by year, Inventory stood at $27.3 million in 2021, then crashed by 51.35% to $13.3 million in 2022, then surged by 80.3% to $24.0 million in 2023, then crashed by 41.12% to $14.1 million in 2024, then crashed by 35.34% to $9.1 million in 2025.
  • Business Quant data shows Inventory for LGNDZ at $9.1 million in Q4 2025, $11.9 million in Q3 2025, and $15.5 million in Q2 2025.